提高重组腺相关病毒载体（rAAV）转基因的表达效果，减少载体用量，降低机体的免疫反应，是困扰rAAV临床应用的一个重大问题。PI3K途径是rAAV载体在细胞内传递过程和转基因表达的一个重要途径，同时也是白藜芦醇参与多种肿瘤细胞走向凋亡的重要通路。本项目研究拟以白藜芦醇（resveratrol）与rAAV载体联合使用，表达kallistatin(KAL)基因，并针对给药时效、量效、给药顺序以及给药频率等因素进行正交设计，以增加10倍的KAL表达量为目标，进行体外、体内用药条件优化。试验通过对rAAV胞内转移的涉及的细胞受体、蛋白酶体、氧化应激、微管微丝、金属蛋白酶等基因和蛋白进行检查，尤其是PI3K-AKT上下通路蛋白、基因的检查，以探明resveratrol促进rAAV转基因表达的作用机制，为resveratrol与rAAV联合用药提供理论依据。

It is an important problem to improve the transgenic expression of recombinant adeno-associated virus (rAAV) for reducing the vector dose and the immune response of the body. PI3K pathway is ont only an important way of rAAV transfer process in cells and transgenic expression, but also the important pathway of resveratrol acting on many tumor cells. This project intends to use resveratrol in combination with rAAV vector to express kallistatin (rAAV-KAL). We will conduct orthogonal design for optimal condition and aim at increasing the expression level of kallistatin(KAL) by 10 times in vitro and in vivo. In order to ascertain the mechanism of resveratrol promote the transgenic expression of rAAV, the genes and proteins such as cell receptors, proteasome, oxidative stress, microtubule microfilament, metal protease and PI3K pathway will be inspected. genetic testing. This study will providetheoretical foundation for resveratrol and rAAV combination.